Shopping Cart 0
Cart Subtotal
USD 0

UCB SA (UCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA (UCB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13

UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

UCB SA, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19

Venture Financing 20

Element Genomics Raises Funds through Venture Financing 20

Syndesi Therapeutics Raises USD21 Million in Series A Financing 21

Element Genomics Raises USD5 Million in Venture Financing 23

Lumos Pharma Raises USD34 Million in Series B Financing Round 24

Clementia Pharma Secures USD60 Million Venture Financing 26

Clementia Pharma Raises USD60 Million in Venture Financing 28

Dermira Raises USD51 Million In Series C Venture Financing 30

Private Equity 32

Paragon Partners to Acquire UCB Innere Medizin from UCB 32

Partnerships 33

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 33

Q-State Biosciences Enters into Research Agreement with UCB 34

NovAliX Enters into Agreement with UCB Biopharma 35

MC10 Enters into Agreement with UCB 36

MRC Technology, UCB and University of Leicester Enter into Agreement 37

UCB Enters into Research Agreement with Baylor College of Medicine 38

Evotec Partners with UCB 39

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40

Beryllium Enters into Agreement with UCB to Develop Drug Targets 41

Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42

Sanofi Enters Into Agreement With UCB For Drug Discovery 43

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44

Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45

Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46

UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47

UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48

UCB Enters Into Research Agreement With Five Prime Therapeutics 49

ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50

biOasis Technologies Enters Into Research Agreement With UCB 51

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52

UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53

UCB Enters Into Co-Development Agreement With Harvard University 54

UCB Enters Into Co-Development Agreement With Imperial College London 55

UCB Enters Into Co-Development Agreement With Oxford University 56

Nodality Enters Into Co-Developement Agreement With UCB Pharma 57

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58

Otsuka Pharma Amends Co-Development Agreement With UCB 60

Licensing Agreements 62

UCB Enters into Licensing Agreement with Five Prime Therapeutics 62

Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63

Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64

Zai Lab Enters into Licensing Agreement with UCB 65

UCB Exercises Option for Licensing Agreement with Oncodesign 66

King's College Enters into Licensing Agreement with UCB 67

King's College London Enters Into Licensing Agreement with UCB 68

Neuropore Therapies Enters into Licensing Agreement with UCB 69

UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70

UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71

Equity Offering 72

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72

Syndesi Therapeutics Spins Out from UCB 74

Dermira Raises USD7.5 Million in Private Placement of Shares 75

Wilex Completes Private Placement Of Shares For USD 12.4 Million 77

Debt Offering 78

UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78

UCB Completes Private Placement Of 4.125% Bonds Due 2021 For USD 473.2 Million 79

UCB Completes Public Offering Of Bonds For USD 326 Million 80

Asset Transactions 81

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 82

Exemed Pharma Acquires Indian Production Facility of UCB 83

Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84

Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85

Acquisition 86

UCB Acquires Element Genomics 86

Biogen and UCB May Acquire Acorda Therapeutics 87

UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88

Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89

Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90

UCB Acquires 51% Stake In Meizler Biopharma 92

UCB SA-Key Competitors 93

UCB SA-Key Employees 94

UCB SA-Locations And Subsidiaries 95

Head Office 95

Other Locations & Subsidiaries 95

Joint Venture 98

Recent Developments 99

Financial Announcements 99

Oct 30, 2018: UCB first nine months interim report 2018: UCB tracking well towards full year financial outlook 99

Jul 26, 2018: UCB half year report 2018: UCB continues its growth path 101

Apr 25, 2018: UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook 103

Feb 22, 2018: UCB Full Year Report 2017 105

Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 106

Jul 27, 2017: UCB with a strong first half year 2017-giving rise to the financial outlook for 2017 107

Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 110

Corporate Communications 111

Mar 24, 2017: UCB General Meeting on 27 April 2017 111

Government and Public Interest 112

Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma-UCB SA] 112

May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 113

Product News 114

09/21/2017: UCB's anti-epileptic drug VIMPAT (lacosamide) receives EU approval for paediatric use 114

08/25/2017: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients 115

07/20/2017: UCB Pharma Receives CHMP Positive Opinion for Vimpat 116

Product Approvals 117

Sep 01, 2017: Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg 117

Mar 13, 2017: UCB Pharmas Vimpat Rejects For Use Within NHS Scotland 118

Clinical Trials 119

Apr 26, 2017: Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 119

Other Significant Developments 120

Oct 05, 2018: New online patent-search tool launched 120

Sep 05, 2018: New approach accelerates drug discovery 121

Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 122

Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 123

Appendix 124

Methodology 124

About GlobalData 124

Contact Us 124

Disclaimer 124


List Of Figure

List of Figures

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

UCB SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13

UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19

Element Genomics Raises Funds through Venture Financing 20

Syndesi Therapeutics Raises USD21 Million in Series A Financing 21

Element Genomics Raises USD5 Million in Venture Financing 23

Lumos Pharma Raises USD34 Million in Series B Financing Round 24

Clementia Pharma Secures USD60 Million Venture Financing 26

Clementia Pharma Raises USD60 Million in Venture Financing 28

Dermira Raises USD51 Million In Series C Venture Financing 30

Paragon Partners to Acquire UCB Innere Medizin from UCB 32

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 33

Q-State Biosciences Enters into Research Agreement with UCB 34

NovAliX Enters into Agreement with UCB Biopharma 35

MC10 Enters into Agreement with UCB 36

MRC Technology, UCB and University of Leicester Enter into Agreement 37

UCB Enters into Research Agreement with Baylor College of Medicine 38

Evotec Partners with UCB 39

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40

Beryllium Enters into Agreement with UCB to Develop Drug Targets 41

Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42

Sanofi Enters Into Agreement With UCB For Drug Discovery 43

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44

Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45

Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46

UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47

UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48

UCB Enters Into Research Agreement With Five Prime Therapeutics 49

ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50

biOasis Technologies Enters Into Research Agreement With UCB 51

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52

UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53

UCB Enters Into Co-Development Agreement With Harvard University 54

UCB Enters Into Co-Development Agreement With Imperial College London 55

UCB Enters Into Co-Development Agreement With Oxford University 56

Nodality Enters Into Co-Developement Agreement With UCB Pharma 57

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58

Otsuka Pharma Amends Co-Development Agreement With UCB 60

UCB Enters into Licensing Agreement with Five Prime Therapeutics 62

Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63

Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64

Zai Lab Enters into Licensing Agreement with UCB 65

UCB Exercises Option for Licensing Agreement with Oncodesign 66

King's College Enters into Licensing Agreement with UCB 67

King's College London Enters Into Licensing Agreement with UCB 68

Neuropore Therapies Enters into Licensing Agreement with UCB 69

UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70

UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72

Syndesi Therapeutics Spins Out from UCB 74

Dermira Raises USD7.5 Million in Private Placement of Shares 75

Wilex Completes Private Placement Of Shares For USD 12.4 Million 77

UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78

UCB Completes Private Placement Of 4.125% Bonds Due 2021 For USD 473.2 Million 79

UCB Completes Public Offering Of Bonds For USD 326 Million 80

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 82

Exemed Pharma Acquires Indian Production Facility of UCB 83

Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84

Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85

UCB Acquires Element Genomics 86

Biogen and UCB May Acquire Acorda Therapeutics 87

UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88

Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89

Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90

UCB Acquires 51% Stake In Meizler Biopharma 92

UCB SA, Key Competitors 93

UCB SA, Key Employees 94

UCB SA, Subsidiaries 95

UCB SA, Joint Venture 98

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

UCB SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA (UCB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13

UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

UCB SA, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19

Venture Financing 20

Element Genomics Raises Funds through Venture Financing 20

Syndesi Therapeutics Raises USD21 Million in Series A Financing 21

Element Genomics Raises USD5 Million in Venture Financing 23

Lumos Pharma Raises USD34 Million in Series B Financing Round 24

Clementia Pharma Secures USD60 Million Venture Financing 26

Clementia Pharma Raises USD60 Million in Venture Financing 28

Dermira Raises USD51 Million In Series C Venture Financing 30

Private Equity 32

Paragon Partners to Acquire UCB Innere Medizin from UCB 32

Partnerships 33

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 33

Q-State Biosciences Enters into Research Agreement with UCB 34

NovAliX Enters into Agreement with UCB Biopharma 35

MC10 Enters into Agreement with UCB 36

MRC Technology, UCB and University of Leicester Enter into Agreement 37

UCB Enters into Research Agreement with Baylor College of Medicine 38

Evotec Partners with UCB 39

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40

Beryllium Enters into Agreement with UCB to Develop Drug Targets 41

Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42

Sanofi Enters Into Agreement With UCB For Drug Discovery 43

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44

Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45

Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46

UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47

UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48

UCB Enters Into Research Agreement With Five Prime Therapeutics 49

ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50

biOasis Technologies Enters Into Research Agreement With UCB 51

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52

UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53

UCB Enters Into Co-Development Agreement With Harvard University 54

UCB Enters Into Co-Development Agreement With Imperial College London 55

UCB Enters Into Co-Development Agreement With Oxford University 56

Nodality Enters Into Co-Developement Agreement With UCB Pharma 57

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58

Otsuka Pharma Amends Co-Development Agreement With UCB 60

Licensing Agreements 62

UCB Enters into Licensing Agreement with Five Prime Therapeutics 62

Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63

Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64

Zai Lab Enters into Licensing Agreement with UCB 65

UCB Exercises Option for Licensing Agreement with Oncodesign 66

King's College Enters into Licensing Agreement with UCB 67

King's College London Enters Into Licensing Agreement with UCB 68

Neuropore Therapies Enters into Licensing Agreement with UCB 69

UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70

UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71

Equity Offering 72

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72

Syndesi Therapeutics Spins Out from UCB 74

Dermira Raises USD7.5 Million in Private Placement of Shares 75

Wilex Completes Private Placement Of Shares For USD 12.4 Million 77

Debt Offering 78

UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78

UCB Completes Private Placement Of 4.125% Bonds Due 2021 For USD 473.2 Million 79

UCB Completes Public Offering Of Bonds For USD 326 Million 80

Asset Transactions 81

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 82

Exemed Pharma Acquires Indian Production Facility of UCB 83

Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84

Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85

Acquisition 86

UCB Acquires Element Genomics 86

Biogen and UCB May Acquire Acorda Therapeutics 87

UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88

Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89

Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90

UCB Acquires 51% Stake In Meizler Biopharma 92

UCB SA-Key Competitors 93

UCB SA-Key Employees 94

UCB SA-Locations And Subsidiaries 95

Head Office 95

Other Locations & Subsidiaries 95

Joint Venture 98

Recent Developments 99

Financial Announcements 99

Oct 30, 2018: UCB first nine months interim report 2018: UCB tracking well towards full year financial outlook 99

Jul 26, 2018: UCB half year report 2018: UCB continues its growth path 101

Apr 25, 2018: UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook 103

Feb 22, 2018: UCB Full Year Report 2017 105

Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 106

Jul 27, 2017: UCB with a strong first half year 2017-giving rise to the financial outlook for 2017 107

Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 110

Corporate Communications 111

Mar 24, 2017: UCB General Meeting on 27 April 2017 111

Government and Public Interest 112

Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma-UCB SA] 112

May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 113

Product News 114

09/21/2017: UCB's anti-epileptic drug VIMPAT (lacosamide) receives EU approval for paediatric use 114

08/25/2017: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients 115

07/20/2017: UCB Pharma Receives CHMP Positive Opinion for Vimpat 116

Product Approvals 117

Sep 01, 2017: Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg 117

Mar 13, 2017: UCB Pharmas Vimpat Rejects For Use Within NHS Scotland 118

Clinical Trials 119

Apr 26, 2017: Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 119

Other Significant Developments 120

Oct 05, 2018: New online patent-search tool launched 120

Sep 05, 2018: New approach accelerates drug discovery 121

Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 122

Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 123

Appendix 124

Methodology 124

About GlobalData 124

Contact Us 124

Disclaimer 124


List Of Figure

List of Figures

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

UCB SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

UCB SA, Deals By Therapy Area, 2012 to YTD 2018 11

UCB SA, Medical Devices Deals, 2012 to YTD 2018 13

UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19

Element Genomics Raises Funds through Venture Financing 20

Syndesi Therapeutics Raises USD21 Million in Series A Financing 21

Element Genomics Raises USD5 Million in Venture Financing 23

Lumos Pharma Raises USD34 Million in Series B Financing Round 24

Clementia Pharma Secures USD60 Million Venture Financing 26

Clementia Pharma Raises USD60 Million in Venture Financing 28

Dermira Raises USD51 Million In Series C Venture Financing 30

Paragon Partners to Acquire UCB Innere Medizin from UCB 32

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 33

Q-State Biosciences Enters into Research Agreement with UCB 34

NovAliX Enters into Agreement with UCB Biopharma 35

MC10 Enters into Agreement with UCB 36

MRC Technology, UCB and University of Leicester Enter into Agreement 37

UCB Enters into Research Agreement with Baylor College of Medicine 38

Evotec Partners with UCB 39

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40

Beryllium Enters into Agreement with UCB to Develop Drug Targets 41

Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42

Sanofi Enters Into Agreement With UCB For Drug Discovery 43

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44

Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45

Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46

UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47

UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48

UCB Enters Into Research Agreement With Five Prime Therapeutics 49

ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50

biOasis Technologies Enters Into Research Agreement With UCB 51

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52

UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53

UCB Enters Into Co-Development Agreement With Harvard University 54

UCB Enters Into Co-Development Agreement With Imperial College London 55

UCB Enters Into Co-Development Agreement With Oxford University 56

Nodality Enters Into Co-Developement Agreement With UCB Pharma 57

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58

Otsuka Pharma Amends Co-Development Agreement With UCB 60

UCB Enters into Licensing Agreement with Five Prime Therapeutics 62

Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63

Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64

Zai Lab Enters into Licensing Agreement with UCB 65

UCB Exercises Option for Licensing Agreement with Oncodesign 66

King's College Enters into Licensing Agreement with UCB 67

King's College London Enters Into Licensing Agreement with UCB 68

Neuropore Therapies Enters into Licensing Agreement with UCB 69

UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70

UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72

Syndesi Therapeutics Spins Out from UCB 74

Dermira Raises USD7.5 Million in Private Placement of Shares 75

Wilex Completes Private Placement Of Shares For USD 12.4 Million 77

UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78

UCB Completes Private Placement Of 4.125% Bonds Due 2021 For USD 473.2 Million 79

UCB Completes Public Offering Of Bonds For USD 326 Million 80

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 82

Exemed Pharma Acquires Indian Production Facility of UCB 83

Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84

Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85

UCB Acquires Element Genomics 86

Biogen and UCB May Acquire Acorda Therapeutics 87

UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88

Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89

Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90

UCB Acquires 51% Stake In Meizler Biopharma 92

UCB SA, Key Competitors 93

UCB SA, Key Employees 94

UCB SA, Subsidiaries 95

UCB SA, Joint Venture 98

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

UCB SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.